# Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

> **NCT07177092** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jianxing He** · enrollment: 118 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- EGFR

## Interventions

- **PROCEDURE:** Surgery
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT07177092
- **Lead sponsor:** Jianxing He
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2028-10-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07177092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07177092, "Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07177092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*